We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

GSK GSK stock has risen 16.9% year to date compared ... new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also witnessing strong patient ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

ViiV – which is majority-owned by GSK – has said Cabenuva is central to its plans to grow its HIV sales over the next five years alongside long-acting injectable Apretude (cabotegravir), an ...

GSK posted 13% growth in HIV sales in 2024, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. Gilead Sciences currently carries a Zacks Rank ...

GSK looks like it is starting to show the benefit of a revamp of its business under chief executive Emma Walmsley, with recent product launches driving a 10% rise in sales in the first quarter of ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...